Related Experiment Video

Updated: Jul 10, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.7K

PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas

Caterina Mancarella1, Andrea Morrione2, Katia Scotlandi1

  • 1Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.

International Journal of Molecular Sciences
|November 25, 2023
PubMed

Insights

Targeted protein degradation (TPD) offers a novel approach for treating rare pediatric sarcomas. This innovative therapy, utilizing proteolysis-targeting chimeras (PROTACs), shows promise for overcoming limitations of current targeted therapies in sarcoma treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Sarcomas are diverse pediatric cancers with over 100 subtypes, often lacking actionable mutations for targeted therapy.
  • Current targeted therapies for sarcomas show limited efficacy in a minority of patients due to rarity and target limitations.
  • Targeted protein degradation (TPD) is an emerging modality with potential for treating cancers, including those with undruggable targets.

Purpose of the Study:

  • To review the features of PROTACs and PROTAC-derived genetic systems.
  • To explore the potential of TPD in overcoming challenges in sarcoma targeted therapy.
  • To highlight TPD's role in advancing molecular and personalized medicine for sarcomas.

Main Methods:

  • Review of scientific literature on PROTAC technology and its application in cancer.
  • Analysis of TPD's potential to address drug resistance, target specificity, and undruggable targets in sarcomas.
  • Discussion of PROTAC-derived genetic systems for target validation and therapeutic strategies.

Main Results:

  • PROTACs offer a new strategy to induce targeted protein degradation, addressing previously undruggable targets.
  • TPD has the potential to overcome key limitations of conventional targeted therapies in various sarcoma subtypes.
  • PROTAC technology may enhance specificity and efficacy, potentially improving patient outcomes in sarcoma treatment.

Conclusions:

  • TPD represents a promising frontier for developing novel sarcoma therapies.
  • Further research into PROTACs and related systems could revolutionize personalized medicine for sarcomas.
  • Targeted protein degradation holds significant potential to improve treatment options for pediatric and adolescent sarcomas.
Keywords:
BET proteinsBRD9PROTACSMARCA4degradation tagfusion genessarcomastargeted therapyubiquitination

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.7K
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.3K
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
766
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K